An object of the present invention is to provide a novel tetrahydroazepine compound and a process for producing the same. The present invention relates to a tetrahydroazepine compound represented by the formula (10) or a salt thereof, and a process for producing the said compound or a salt thereof. ##STR00001## (In the formula, R.sup.1 is an optionally substituted alkyl group, R.sup.2 is an optionally substituted alkyl group and one of the XY bond and the YZ bond is a carbon-carbon double bond and the other is a carbon-carbon single bond).

An object of the present invention is to provide a novel tetrahydroazepine compound and a process for producing the same. The present invention relates to a tetrahydroazepine compound represented by the formula (10) or a salt thereof, and a process for producing the said compound or a salt thereof. ##STR00001## (In the formula, R.sup.1 is an optionally substituted alkyl group, R.sup.2 is an optionally substituted alkyl group and one of the XY bond and the YZ bond is a carbon-carbon double bond and the other is a carbon-carbon single bond).

The present invention relates to heterocyclic compounds and electronic devices, in particular organic electroluminescent devices, containing these compounds.

The present invention relates to methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof. The resulting products are useful in the treatment of proliferative diseases and infectious diseases.

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: ##STR00001## Pharmaceutical compositions containing said compounds, and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.

The present invention relates to methods for the treatment or prevention of symptoms associated with trauma and stressor-related disorders, in which exposure to a traumatic or stressful event is listed explicitly as a diagnostic criterion. These include reactive attachment disorder, disinhibited social engagement disorder, post-traumatic stress disorder (PTSD), acute stress disorder, and adjustment disorders. The present invention also relates to pharmaceutical compositions comprising opipramol alone, or in combination with another agent for the treatment or prevention of symptoms associated with trauma and stressor-related disorders. The present invention also relates to transdermal formulations of pharmaceutical compositions comprising opipramol alone, or in combination with another agent, for the treatment or prevention of symptoms associated with trauma and stressor-related disorders.

Provided are a novel compound and an organic electronic device using the same. The novel compound is represented by the following Formula (I): ##STR00001##

Provided are a novel compound and an organic electronic device using the same. The novel compound is represented by the following Formula (I): ##STR00001##